Introduction {#s1}
============

In the United States, pharmaceuticals are heavily promoted to providers and patients. The pharmaceutical industry spent nearly \$30 billion dollars in 2005 on marketing and promotion, of which 84% went toward physician detailing and free samples, with less devoted to professional advertising and direct-to-consumer advertising (DTCA) [@pone.0055504-Donohue1], [@pone.0055504-Rosenthal1]. Spending varied considerably by product, although both detailing and DTCA tended to favor drugs with broader clinical indications for use [@pone.0055504-Campbell1]. Pharmaceutical promotion can influence demand for prescription drugs [@pone.0055504-Rosenthal2], increase physician visits for conditions treated by heavily advertised drugs [@pone.0055504-Iizuka1] and affect physician prescribing [@pone.0055504-Donohue2].

Little is known about how pharmaceutical companies have altered promotional spending in response to major health care changes. First, during the past decade there has been a slowdown in new drug introductions. During the second half of the 1990s, the FDA approved a large number of small molecule therapies for common conditions, including many drugs that were the first of their kind. These "blockbuster" drugs were heavily marketed, resulting in a 162% increase in total promotional spending between 1996 and 2005 [@pone.0055504-Donohue1]. In recent years, however, blockbuster drugs have faced increasing competition from generics, as well as branded rivals, with the generic share of total prescriptions increasing markedly from 63% in 2006 to nearly 80% in 2010 [@pone.0055504-IMS1]. Fewer new drugs have been approved annually in recent years [@pone.0055504-Aitken1], and a greater proportion of those introduced have been for orphan conditions [@pone.0055504-Generic1]. Second, drugs manufactured using biologic processes, or "biologics", represent an increasing proportion of newly approved products and drugs sales [@pone.0055504-Trusheim1], [@pone.0055504-Mullins1]. Biologics comprised over 40% of products in late stage research and development in 2009, suggesting that they may account for an increasing proportion of new products launched in the near future [@pone.0055504-Trusheim1]. Since these products are often used by a smaller number of patients, administered parenterally by providers, and sold at much higher prices, the promotional strategies may differ substantially compared to small molecule therapies. Finally, in response to mounting empirical evidence as well as legal challenges, media scrutiny [@pone.0055504-Hensley1], and the recommendations of professional societies [@pone.0055504-American1], numerous medical centers have limited pharmaceutical sales representatives access to physicians [@pone.0055504-Rothman1]--[@pone.0055504-FughBerman1]. Furthermore, certain states now require disclosure of gifts from pharmaceutical companies to providers [@pone.0055504-Chimonas1]. While there is some evidence of decreases in industry interaction with office-based physicians [@pone.0055504-Campbell2], [@pone.0055504-OReilly1], it is unclear how industry practices have changed in response to these provisions.

We examined trends in promotion to consumers and providers over the last decade. We hypothesized decreases in absolute spending on promotion to providers and DTCA, with an increasing share of detailing devoted to specialists given the expanding role of biologics. In addition to trends for the pharmaceutical industry overall, we compared the promotional strategies of top-selling small molecule and biologic therapies. Finally, to determine whether trends in promotion were correlated with changes in the pharmaceutical pipeline, we examined the number of products and spending per product promoted.

Methods {#s2}
=======

Data {#s2a}
----

We used the IMS Health Integrated Promotional Services™ to obtain data on detailing, free samples dispensed to providers, and journal advertisements. We obtained data from SDI on spending for electronic promotion (e.g., Internet) targeting providers and for meetings and conferences. IMS Health detailing estimates are derived from a nationally representative audit of office- and hospital-based providers as well as pharmacy directors. Office-based detailing includes spending on service visits associated with sample distribution. Estimates of units of free samples dispensed to physicians are derived from an audit of office-based physician practices, while their retail value is calculated based on suggested retail prices. Journal advertising data is collected through a census of all medical journals. Using directory information from the American Medical Association, IMS also reports detailing expenditures by physician specialty. SDI spending is based on a monthly audit of approximately 4,000 office-based providers representing 19 specialties. Data are collected and projected by region and specialty to represent a universe of approximately 380,000 practicing providers. Finally, Kantar Media provided industry-wide and product-specific DTCA expenditures accounting for television, magazine, radio, outdoor, newspaper, and Internet promotion. These estimates are drawn from a sample of national media such as network TV and national newspapers as well as local media sampled at the Designated Media Area level.

We used IMS Health sales figures [@pone.0055504-IMS1], supplemented for certain therapies with data from the IMS Health National Sales Perspectives™, in order to calculate promotion and marketing as a percentage of total sales. Estimates of the annual sales were calculated based on unit sales from both retail and non-retail channels and ex-manufacturer invoices (amount paid to wholesalers or manufacturers net of prompt payment discounts). We obtained data on the number of products on the market and, of these, the number promoted each year using IMS Health National Sales Perspectives™ and Integrated Promotional Services™. We used a data set of drug launches [@pone.0055504-Trusheim1], supplemented for 2009 and 2010 with the number of new molecular entities approved by the Food and Drug Administration [@pone.0055504-United1], to determine the number of new molecular entities per year.

Biologic therapies were defined as those manufactured using biologic processes [@pone.0055504-Trusheim1], while the remainder of products were categorized as small molecules.

Analyses {#s2b}
--------

We used descriptive statistics to characterize six aspects of promotion to providers: the retail value of free samples, office-based detailing, hospital-based detailing, journal advertising, epromotion and conferences and meetings. We quantified the absolute and relative magnitude of annual total promotional efforts towards providers. We also assessed the concentration of promotion for top-selling small molecules and biologic therapies.

We obtained a list of the top-selling U.S. and European biologics in 2010 [@pone.0055504-Rader1]. We then identified additional biologics with high sales expenditures [@pone.0055504-Aggarwal1] and used the IMS Health National Sales Perspectives™ to rank these therapies. Sales and promotional expenditures were aggregated across all formulations of a brand, and for the few molecules available both as monotherapies and fixed-dose combinations, we excluded sales and promotional spending associated with combination therapies. Except where otherwise noted, data on sales and promotional spending were adjusted to 2010 dollars using the Consumer Price Index -- All Urban [@pone.0055504-United2].

Results {#s3}
=======

Trends in Overall and Provider Promotion {#s3a}
----------------------------------------

[Table 1](#pone-0055504-t001){ref-type="table"} characterizes aggregate trends in marketing and promotion. Total inflation-adjusted promotional spending peaked in 2004 both in terms of absolute spending (\$36.1 billion) and spending relative to sales (13.4%). Afterward, spending declined each year to \$27.7B (9.0% of sales) by 2010. Nearly all forms of promotion saw declines beginning in 2005. The retail value of free samples declined 23%, or 11% when not adjusted for inflation, from \$18.1 B in 2004 to \$13.9B in 2010. The expenditure shares across the three major promotional categories were remarkably stable. Despite a more than two-fold relative increase in electronic promotion, this category accounted for less than 2% of provider promotion in 2010.

10.1371/journal.pone.0055504.t001

###### Pharmaceutical promotion to consumers and providers 2001--2010.
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                                                                2001     2002     2003     2004     2005     2006     2007     2008     2009     2010
  ----------------------------------------------------------- -------- -------- -------- -------- -------- -------- -------- -------- -------- --------
  Direct-to-consumer advertising (millions of 2010 dollars)                                                                                    
  Television                                                   2,184    2,061    2,367    3,213    3,150    3,270    3,194    2,951    2,919    2,375
  Print                                                        1,242    1,242    1,606    1,651    1,823    2,291    2,132    1,617    1,587    1,747
  Internet                                                       27       42       72      214      181      230      105      141      312      202
  Radio                                                          46       51       73       67       68       87       48       24       43       44
  Outdoor                                                        2        6        6        6        8        13       4        3        6        3
  Total                                                        3,500    3,402    4,124    5,151    5,231    5,891    5,483    4,738    4,868    4,371
   As percentage of sales                                       1.7      1.4      1.6      1.9      1.9      2.0      1.9      1.6      1.6      1.4
  Promotion to providers (millions of 2010 dollars)                                                                                            
  Office-based promotion                                       5,897    6,450    7,442    7,621    6,892    6,780    6,147    6,043    5,906    5,306
  Hospital-based promotion                                      864     1,071    1,005    1,059     881      718      620      490      491      479
  Journal advertising                                           523      578      582      628      531      570      494      392      320      326
  Free samples (retail value)                                  12,884   14,455   16,057   18,056   16,318   14,970   15,614   14,193   14,416   13,850
  Epromotion (SDI)                                               --       --      251      255      314      356      415      497      532      525
  Conferences and meetings (SDI)                               2,605    2,644    2,890    3,295    3,027    2,851    2,910    2,993    2,952    2,840
  Total                                                        22,773   25,197   28,229   30,915   27,963   26,242   26,201   24,609   24,616   23,326
   As percentage of sales                                       10.8     10.7     10.9     11.4     10.1     9.0      8.9      8.5      8.1      7.6
  All DTCA and promotion to providers (\$2010 millions)        26,274   28,599   32,352   36,065   33,194   32,133   31,685   29,347   29,484   27,697
  All sales (\$2010 billions)                                   212      236      260      270      276      292      296      290      305      307
   As percentage of sales                                       12.4     12.1     12.5     13.4     12.0     11.0     10.7     10.1     9.7      9.0
  Number of new molecular entities launched                      31       28       30       21       20       27       21       19       26       21
  Number of products marketed and promoted                     2,920    3,087    3,056    3,105    3,094    2,680    2,730    2,660    2,576    2,474
  Average promotion per product (\$millions)                    9.0      9.3      10.6     11.6     10.7     12.0     11.6     11.0     11.4     11.2

All financial data were adjusted to 2010 dollars, utilizing the Consumer Price Index -- All Urban.

Sources: Direct-to-consumer advertising data provided by Kantar Media; promotion to professionals data derived from the IMS Health Integrated Promotional Services™, 2002--2010 with the exception of data regarding epromotion and conferences and meetings which was derived from the SDI Physician Meeting and Event Audit and SDI ePromotion Audit; provider promotion for 2001 derived from reference \#1; sales data derived from IMS Health Use of Medicines 2010 Report; newly launched molecular entities derived from reference \#10; number of products marketed and promoted derived from IMS Health Integrated Promotional Services™ and includes products with any spending targeting providers.

Trends in Direct-to-consumer Advertising (DTCA) {#s3b}
-----------------------------------------------

DTCA peaked at \$5.9B in 2006 followed by a 25% decline to \$4.4B by 2010. As a percentage of total promotional spending, DTCA increased from 12% in 2002 to 18% in 2006, but declined modestly to 16% by 2010. During this period, television accounted for a decreasing proportion of all DTCA, declining from 62% in 2001 to 54% by 2010. Print DTCA increased 84% 2001--2006, but then declined 24% by 2010. In 2010, internet promotion accounted for less than 5% of overall consumer promotion.

Drug Launches and Overall Number of Products Promoted {#s3c}
-----------------------------------------------------

The number of new molecular entities launched ranged from 19 to 31 across the study period, with the greatest numbers of new molecular entities introduced between 2001 and 2003 ([Table 1](#pone-0055504-t001){ref-type="table"}). Declines in the number of products promoted paralleled declines in promotional spending. The average promotional spending per product actually increased from \$9.0M (2001) to \$12.0M (2006), then declined modestly to \$11.2M (2010).

Promotion of Top-selling Agents {#s3d}
-------------------------------

Among the 25 top-selling products of 2010 listed in [Table 2](#pone-0055504-t002){ref-type="table"}, 16 were small molecule therapies and the remaining nine were biologics.

10.1371/journal.pone.0055504.t002

###### U.S. sales revenue and promotional spending for leading selling prescription medicines according to dollar sales in 2010.
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  Rank        Therapy      Type of therapy   U.S. Sales (billions)   Promotion (millions)   Percentage of sales                                        
  ------- --------------- ----------------- ----------------------- ---------------------- --------------------- ------ ------- ------ ------- ------- -------
  1           Lipitor      Small molecule             7.2                   272.0                  97.3           7.6    359.7   4.3    468.8   740.8   10.3%
  2           Nexium       Small molecule             6.4                    16.7                  32.5           2.3    208.5   0.7    244.0   260.7   4.1%
  3           Plavix       Small molecule             6.1                   127.3                  60.1           9.1    93.3    0.2    162.7   290.0   4.8%
  4          Seroquel      Small molecule             5.2                    80.6                  51.2           11.8   91.0    0.0    153.9   234.5   4.5%
  5        Advair Diskus   Small molecule             4.7                   200.5                  47.5           1.8    343.4   0.0    392.7   593.2   12.6%
  6           Abilify      Small molecule             4.6                   155.7                  49.7           6.1    412.7   0.0    468.5   624.2   13.6%
  7          Singulair     Small molecule             4.1                    70.3                  69.5           3.6    309.5   0.04   382.6   452.9   11.0%
  8           Crestor      Small molecule             3.8                    95.3                  101.5          7.0    389.7   1.0    499.2   594.5   15.6%
  9            Actos       Small molecule             3.5                    40.7                  48.9           1.5    202.2   0.0    252.6   293.3   8.4%
  10          Epogen          Biologic                3.3                     0                     0.4           0.1     0.0    0.0     0.4     0.4    0.01%
  11         Remicade         Biologic                3.3                     0                     4.7           0.7     0.3    0.6     6.3     6.3    0.2%
  12          Enbrel          Biologic                3.3                    71.5                   9.9           0.9     8.1    1.2    20.1    91.6    2.8%
  13          Zyprexa      Small molecule             3.3                    1.2                   16.0           5.8    174.1   0.0    195.9   197.1   6.0%
  14         Cymbalta      Small molecule             3.2                   206.0                  93.6           7.2    309.6   4.0    414.4   620.4   19.4%
  15          Avastin         Biologic                3.1                   0.0007                  2.8           1.6     0.0    2.2     6.6     6.6    0.2%
  16         Oxycontin     Small molecule             3.1                    0.1                    9.9           0.9     0.0    2.6    13.4    13.5    0.4%
  17          Lantus          Biologic                3.0                    46.5                  37.2           4.7    58.3    8.3    108.5   154.9   5.1%
  18         Neulasta         Biologic                3.0                    0.3                    1.4           0.2     0.0    0.7     2.3     2.6    0.1%
  19          Humira          Biologic                2.9                    34.1                  12.9           3.8    25.4    0.1    42.2    76.3    2.6%
  20          Lexapro      Small molecule             2.8                    2.1                   108.2          6.7    270.9   13.1   398.8   400.9   14.3%
  21          Rituxan         Biologic                2.8                    0.05                   4.3           0.2     0.0    2.3     6.8     6.9    0.2%
  22          Aricept      Small molecule             2.5                    34.3                  25.5           2.6    154.1   2.2    184.5   218.8   8.8%
  23          Lovenox      Small molecule             2.3                    0.1                    7.3           8.5     3.2    0.0    19.0    19.1    0.8%
  24          Atripla      Small molecule             2.2                    0.8                    2.1           1.0     0.2    0.4     3.7     4.5    0.2%
  25         Copaxone         Biologic                2.2                     0                     4.0           0.7     2.3    0.2     7.2     7.2    0.3%
  TOTAL         --               --                   91                    1,456                   20%            2%     77%     1%    4,455   5,911   6.4%

Sources: Direct-to-consumer advertising data provided by Kantar Media; promotion to professionals data derived from the IMS Health Integrated Promotional Services™, 2010™ and excludes epromotion and expenditures for conferences and meetings depicted in [Table 1](#pone-0055504-t001){ref-type="table"}; sales data derived from IMS Health Use of Medicines 2010.

Levels and intensities of provider and consumer-directed promotion were generally lower for biologics than small molecule therapies. The top 15 small molecule therapies had an average total promotional spending of \$370 million in 2010 (8.8% of sales) compared to only \$33 million for the top 15 biologics (1.4% of sales).

Products Most Heavily Promoted to Consumers {#s3e}
-------------------------------------------

[Table 3](#pone-0055504-t003){ref-type="table"} displays the 25 drugs most heavily promoted to consumers via DTCA. The drug most heavily promoted to consumers in 2010 was Lipitor with \$272M devoted to DTCA alone followed by Cialis (\$216M) and Cymbalta (\$206M). DTCA was concentrated in a small number of products. Only two of the top 25 consumer-promoted products, etanercept (Enbrel) and golimumab (Simponi), were biologic therapies, whereas biologics accounted for 9 of the 25 top-selling products.

10.1371/journal.pone.0055504.t003

###### Therapies most heavily promoted through direct-to-consumer advertising, 2010.
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  Ranking                                                      Trade name                                     Type of drug                       Spending in direct-to-consumer advertising (millions)
  -------------------------------------------- ------------------------------------------ ----------------------------------------------------- -------------------------------------------------------
  1                                                             Lipitor                                          Statin                                                   272
  2                                                              Cialis                            Phosphodiesterase type 5 inhibitor                                     216
  3                                                             Cymbalta                       Serotonin-norepinephrine reuptake inhibitor                                206
  4                                                              Advair                    Inhaled corticosteroid and long-acting beta-agonist                            200
  5                                                             Abilify                                  Atypical antipsychotic                                           156
  6                                                            Symbicort                   Inhaled corticosteroid and long-acting beta-agonist                            152
  7                                                             Pristiq                        Serotonin-norepinephrine reuptake inhibitor                                127
  8                                                              Plavix                              Oral thienopyridine antiplatlet                                      127
  9                                                              Lyrica                                      Anticonvulsant                                               112
  10                                                            Chantix                            Nicotinic receptor partial agonist                                     110
  11                                                             Toviaz                                   Muscarinic antagonist                                           109
  12                                                             Viagra                                      PDE5 inhibitor                                               100
  13                                                            Crestor                                          Statin                                                   95
  14                                                             Boniva                                    Oral bisphosphonate                                            85
  15                                                             Lovaza                                    Omega-3 fatty acid                                             81
  16                                                            Seroquel                                 Atypical antipsychotic                                           81
  17                                            Enbrel[\*](#nt105){ref-type="table-fn"}              Tumor necrosis factor inhibitor                                      72
  18                                            Simponi[\*](#nt105){ref-type="table-fn"}             Tumor necrosis factor inhibitor                                      71
  19                                                       Spiriva Handihaler                        Anticholinergic bronchodilator                                       71
  20                                                           Singulair                            Leukotriene receptor antagonists                                      70
  21                                                            Januvia                         Dipeptidyle peptidase-4 (DPP-4) inhibitor                                 65
  22                                                            Restasis                              Cyclosporin topical emulsion                                        58
  23                                                            Vyvanse                                      Psychostimulant                                              58
  24                                                            Trilipix                                         Fibrate                                                  56
  25                                                            Lunesta                                Non-benzodiazepine hypnotic                                        54
  All 25 combined                                                2,805                                                                          
  Total percentage of industry DTCA spending                       64                                                                           

Source: Data provided by Kantar Media.

Biologic therapy.

Promotion of Biologics {#s3f}
----------------------

[Table 4](#pone-0055504-t004){ref-type="table"} reports top US-selling biologics along with product-specific expenditures and promotional spending toward consumers and providers. In 2010, epoetin alfa (Epogen), infliximab (Remicade) and etanercept (Enbrel) led in biologic sales, each with \$3.3B. Among top-selling biologic therapies, 2010 promotion was greatest for exenatide (Byetta) with 20% of its \$571M in US sales dedicated to promotion, followed by insulin detemir (Levemir) with 12% and insulin glargine (Lantus) with 5% of its \$3.0B in U.S. sales dedicated to promotion. Promotion for 17 of the other top-selling 25 biologics was less than 1% of sales.

10.1371/journal.pone.0055504.t004

###### U.S. sales revenue and promotional spending for leading selling biologics according to dollar sales in 2010.\*
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  Rank        Therapy      U.S. Sales (millions)   Promotion   Percentage of sales   Type of provider promotion (thousands)                                    
  ------- --------------- ----------------------- ----------- --------------------- ---------------------------------------- ------- -------- ------- -------- -------
  1           Epogen               3,325               0               447                            447                     0.01%    394      53       0        0
  2          Remicade              3,303               0              6,270                          6,270                    0.2%    4,682     679     277      632
  3           Enbrel               3,291            71,507           20,129                          91,636                   2.8%    9,864     931    8,143    1,192
  4           Avastin              3,091               1              6,643                          6,644                    0.2%    2,837    1,570     0      2,237
  5           Lantus               3,045            46,461           108,474                        154,935                   5.1%    37,178   4,696   58,284   8,316
  6          Neulasta              3,011              252             2,291                          2,543                    0.1%    1,379     217      0       695
  7           Humira               2,929            34,108           42,206                          76,314                   2.6%    12,894   3,778   25,390    144
  8           Rituxan              2,762              45              6,780                          6,825                    0.2%    4,314     202      0      2,264
  9          Copaxone              2,253               0              7,177                          7,177                    0.3%    3,983     723    2,256     216
  10          NovoLog              2,097             4,496           53,130                          57,626                   2.7%    11,261    890    39,566   1,413
  11          Humalog              1,608            13,665           57,805                          71,470                   4.4%    13,075   1,037   35,671   8,022
  12         Herceptin             1,537               0              2,563                          2,563                    0.2%    1,544     264      0       754
  13       Procrit/Eprex           1,466              13              2,277                          2,290                    0.2%    1,295     867      0       115
  14         Lucentis              1,435             2,053             666                           2,719                    0.2%     274      53       0       339
  15          Avonex               1,424              334             4,231                          4,565                    0.3%    2,965     487     258      521
  16          Aranesp              1,305               0              3,470                          3,470                    0.3%    1,971    1,499     0        0
  17         Neupogem               961                0               83                              83                     0.01%     74       9       0        0
  18           Rebif                941               92              4,439                          4,531                    0.5%    3,952     41       0       446
  19         Prevnar-7              829             16,277            6,851                          23,128                   2.8%    4,611     395      0      1,845
  20         Betaseron              826                4              3,148                          3,152                    0.4%    2,857     20       0       271
  21          Synagis               735                0              2,910                          2,910                    0.4%    2,181     728      0        0
  22          Erbitux               709                0              3,640                          3,640                    0.5%    2,318     191      0      1,131
  23          Levemir               673               144            82,889                          83,033                   12.3%   27,125   2,782   48,242   4,740
  24          Byetta                571               42             113,461                        113,503                   19.9%   23,121   1,598   85,194   3,549
  25          Pegasys               512                0              3,447                          3,447                    0.7%    3,016     431      0        0
  TOTAL         --                44,639            189,494          545,427                        734,921                   1.6%     33%      4%      56%      7%

Sources: Direct-to-consumer advertising data provided by Kantar Media; promotion to professionals data derived from the IMS Health Integrated Promotional Services™, 2010 and excludes epromotion and expenditures for conferences and meetings depicted in [Table 1](#pone-0055504-t001){ref-type="table"}; sales data derived from IMS National Sales Perspectives™.

Spending on promotion to providers varied widely across the biologics examined, ranging from only \$83,000 (filgrastim \[Neupogen\]) to more than \$100 million (insulin glargine \[Lantus\] and exenatide \[Byetta\]). For the majority of therapies, office-based detailing accounted for the largest expenditures; however, among the minority of biologics that had any spending on free samples (e.g., Byetta, Lantus, Levemir), this was generally the dominant form of promotion. DTCA for biologics was limited to approximately two-thirds of the 25 therapies examined.

Promotion to Primary Care Physicians and Specialists {#s3g}
----------------------------------------------------

[Table 5](#pone-0055504-t005){ref-type="table"} summarizes trends in detailing and contacts directed at primary care providers and specialists (excluding free samples). The proportion of office-based detailing directed at primary care providers declined modestly from 69% of contacts in 2002 to 63% in 2010. However, smaller decreases were evident in the share of office-based detailing spending targeting primary care physicians.

10.1371/journal.pone.0055504.t005

###### Detailing spending and number contacts with primary care providers and specialists 2001--2010.
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                                        2001    2002    2003    2004    2005    2006    2007    2008    2009    2010
  ------------------------------------ ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  Spending on Office-Based Detailing                                                                           
  Primary Care, %                        --     62.0     --     62.3    61.9    61.0    60.9    60.5    60.6    60.3
  Specialty, %                           --     38.0     --     37.7    38.1    39.0    39.1    39.5    39.4    39.7
  Total (millions \$2010)               5,897   6,450   7,442   7,621   6,892   6,780   6,147   6,043   5,906   5,306
  Office-based Contacts                                                                                        
  Primary Care, %                       69.3    68.6     --     68.5    67.7    63.2    63.1    62.4    62.8    62.6
  Specialty, %                          30.7    31.4     --     31.5    32.3    36.7    36.9    37.5    37.2    37.3
  Total (millions)                      50.8    53.6    67.7    69.0    60.1    58.8    54.0    51.9    48.9    44.6

All data were adjusted to 2010 dollars, utilizing the Consumer Price Index. Primary care providers include those trained in family practice, general practice, internal medicine, osteopathic medicine or pediatrics. Specialty providers were defined as all other provider types, including those trained in subspecialties of internal medicine such as cardiology or gastroenterology.

"--" indicates years when data was not available.

Source: IMS Health Integrated Promotional Services™, 2001--2010.

Discussion {#s4}
==========

After steady increases in pharmaceutical marketing and promotion to consumers and providers during the first half of the last decade, since 2004 pharmaceutical firms have decreased both the absolute value of spending as well as the share of sales devoted to promotion. These declines in promotional spending do not seem to primarily reflect waning consumer purchasing power, since promotion has been declining in the context of rising sales [@pone.0055504-IMS1]. Spending on meetings and electronic promotion has increased, yet these channels still account for only a small fraction of provider promotion. Despite its growth in the first half of the decade, DTCA also represents a minority of promotion and is driven by television advertising. Top-selling biologic therapies had far lower promotional spending per product than did the top small molecule therapies, with substantially less spent on free samples.

Declines in promotion as a percentage of sales since 2005 may result in part from the "graying" of the market [@pone.0055504-Donohue1]. Whereas sales for new drugs accounted for 34% of total sales in 1999 they comprised only 19% of total sales in 2007 [@pone.0055504-Aitken1]. Reductions in new molecular entity approvals are apparent when considering the 1990s. On average, 22 new molecular entities were introduced annually in the 1980s, 31 in the 1990s, and 24 in the 2000s [@pone.0055504-United3].

Declining promotion may also reflect the increasing biologics share of the market [@pone.0055504-Trusheim1]. Biologics often have unique routes of delivery and storage and can be very costly compared to small molecules, with costs for one cancer drug, Avastin, exceeding \$100,000 per year [@pone.0055504-Kolata1]. Given that use of new biologics is concentrated among a smaller number of patients with relatively rare conditions treated primarily by specialists, we would expect promotion to providers and consumers to also be highly targeted.

Despite anecdotal reports [@pone.0055504-Groves1], [@pone.0055504-Brennan1] and calls from stakeholders [@pone.0055504-Brennan1]--[@pone.0055504-Institute1], we did not find evidence of substantial changes in the proportion of provider-targeted promotion accounted for by office-based detailing. In addition, we saw no substantial shifts in the proportion of expenditures targeting primary care providers.

DTCA remains highly concentrated among a small number of products and continues to account for a minority of promotional spending [@pone.0055504-Eichler1]. Declines in DTCA may accelerate as biologics make up a greater share of new therapies. Although relative increases in DTCA through media such as the Internet and social networking have occurred, these expenditures remain a small fraction of overall consumer-targeted promotion.

Our study has several limitations. First, our analyses were not designed to examine promotional content nor the causal effect of promotional expenditures [@pone.0055504-Liang1]--[@pone.0055504-Korenstein1]. Second, some biologics have unique distribution channels and thus our data capture may be incomplete. The difficulty in measuring the extended units for infused and injected therapies also prohibits us from estimating the ratio of promotion to units of utilization. Third, while there are a variety of methods of estimating promotion costs [@pone.0055504-Gagnon1], we have used a conventional commercial definition and have considered only expenditures that are clearly directed at marketing rather than attempting to approximate unmonitored promotion and the R&D proportion that is promotional. Our estimates are similar to those of Donohue et al [@pone.0055504-Donohue1] although here we include estimates of expenditures for conferences and meetings as well as Epromotion to providers. As with prior investigations [@pone.0055504-Donohue1], our estimations of promotion devoted to free samples are based on their approximate retail value and thus may overstate manufacturers' costs. Finally, to the extent medical care prices have increased more rapidly than non-medical care prices, our use of the Consumer Price Index -- All Urban may underestimate the magnitude of the reduction in inflation-adjusted drug spending since 2006.

Manufacturers of branded pharmaceuticals continue to expend considerable sums on promotion to consumers and providers. However, in the context of marketplace changes, firms are decreasing spending but changing little about how expenditures are allocated across types of promotion. An increasing role for biologics to the market may cause more substantial shifts in future promotional patterns.

The statements, findings, conclusions, views, and opinions contained and expressed in this article are based in part on data obtained under license from the following IMS Health Incorporated information service(s): Integrated Promotional Services™, 2001--2010 and IMS Health Incorporated and National Sales Perspectives™, 2001--2010. All Rights Reserved. The statements, findings, conclusions, views, and opinions contained and expressed herein are those of the authors, and are not necessarily those of IMS Health Incorporated or any of its affiliated or subsidiary entities, or of the institutions with whom the authors are affiliated.
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